Lupus & antiphospholipid syndrome
Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus
Authors' conclusion
Based on the evidence obtained in this study, the differences in the efficacy of targeted small-molecule drugs were statistically significant as compared to placebo, but the difference in the safety was not statistically significant.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) in randomized controlled trials (RCTs) of targeted small-molecule drugs (PubMed, Web of Science, Embase, Cochrane Library, to April 25, 2023)
- Participants
- 3,622 patients13 studies
- Comparison
- Targeted small-molecule drugs vs each other and placebo
- Outcome
- SRI-4 response, BICLA response and adverse reactions
Methodological detailsBayesian network meta-regression, Cochrane risk of bias tool
- Bayesian network meta-regression
- Cochrane risk of bias tool
Pooled result
As reported in the abstract
Relative risk (95% CI)P value
Deucravacitinibvs BaricitinibSRI-4 response
1.32(1.04–1.68)
P < 0.05Deucravacitinibvs PlaceboBICLA response
1.55(1.20–2.02)
P < 0.05Safety
| Outcome | P value |
|---|---|
| Adverse eventsTargeted small-molecule drugs vs Placebo | P > 0.05 |
Adverse events
- Targeted small-molecule drugs did not significantly increase the risk of AEs vs placebo
Original publication
Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus. Arthritis Res Ther. Published 10 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →